Nano-X Imaging's (NNOX) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• Nano-X Imaging's stock has been reiterated with a "sell (D-)" rating by Weiss Ratings, highlighting ongoing concerns from analysts.
• While Weiss Ratings maintains a negative outlook, several other analysts have issued ratings ranging from "buy" to "strong-buy", with a consensus rating of "Buy" and an average price target of $8.50.
• The company's recent earnings report revealed a missed earnings estimate with losses per share of ($0.23), compared to the expected ($0.15).

Nano-X Imaging (NASDAQ:NNOX - Get Free Report)'s stock had its "sell (d-)" rating restated by stock analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

A number of other analysts have also recently weighed in on NNOX. D. Boral Capital reaffirmed a "buy" rating and issued a $8.00 price objective on shares of Nano-X Imaging in a report on Friday, September 19th. Alliance Global Partners raised shares of Nano-X Imaging to a "strong-buy" rating in a research note on Monday, August 11th. Finally, LADENBURG THALM/SH SH upgraded shares of Nano-X Imaging to a "strong-buy" rating in a report on Monday, July 14th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Nano-X Imaging currently has a consensus rating of "Buy" and an average price target of $8.50.

Nano-X Imaging Trading Up 8.8%

Shares of NNOX stock opened at $4.33 on Wednesday. The company has a market capitalization of $250.19 million, a PE ratio of -4.81 and a beta of 1.89. The firm has a fifty day simple moving average of $4.09 and a 200-day simple moving average of $4.77. Nano-X Imaging has a twelve month low of $3.60 and a twelve month high of $11.00.

Nano-X Imaging (NASDAQ:NNOX - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.08). Nano-X Imaging had a negative net margin of 468.29% and a negative return on equity of 32.09%. The firm had revenue of $3.04 million during the quarter, compared to analysts' expectations of $3.20 million. Equities research analysts predict that Nano-X Imaging will post -0.92 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC increased its stake in shares of Nano-X Imaging by 1,755.9% in the 1st quarter. GAMMA Investing LLC now owns 7,962 shares of the company's stock valued at $40,000 after acquiring an additional 7,533 shares during the last quarter. Vident Advisory LLC bought a new position in shares of Nano-X Imaging during the 1st quarter worth approximately $55,000. Fox Run Management L.L.C. bought a new position in shares of Nano-X Imaging in the second quarter valued at $57,000. Gainplan LLC bought a new position in shares of Nano-X Imaging in the second quarter valued at $59,000. Finally, BNP Paribas Financial Markets grew its stake in shares of Nano-X Imaging by 193.7% in the second quarter. BNP Paribas Financial Markets now owns 11,994 shares of the company's stock valued at $62,000 after buying an additional 7,910 shares in the last quarter. Institutional investors own 21.49% of the company's stock.

About Nano-X Imaging

Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.